Skip to main content
OPTUS Pharmaceutical Co., Ltd. logo

OPTUS Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 131030 ISIN · KR7131030009 KO Manufacturing
Open in API
Filings indexed 159 across all filing types
Latest filing 2024-02-28 Regulatory Filings
Country KR South Korea
Listing KO 131030

About OPTUS Pharmaceutical Co., Ltd.

http://optuspharm.com/us/main/index.php

OPTUS Pharmaceutical Co., Ltd. is a specialized pharmaceutical company focused on the research, development, manufacturing, and commercialization of ophthalmic products. The company's primary expertise lies in producing sterile, preservative-free, single-dose (unit-dose) formulations. Its therapeutic portfolio addresses conditions such as dry eye syndrome, keratoconjunctival epithelial disease, bacterial conjunctivitis, and glaucoma. In addition to prescription and over-the-counter pharmaceuticals, the company is expanding into a total eye care model through its OUE& brand, which encompasses nutritional supplements (OUEFIT) and cosmeceuticals (OUELAB). The company operates EU-GMP certified manufacturing facilities and distributes its products globally.

Recent filings

Filing Released Lang Actions
신규시설투자등
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Optus Pharm regarding a 'New Facility Investment' (신규시설투자등). It details the investment amount, purpose (production capacity expansion), and timeline, which are typical disclosures for capital expenditure announcements. Since this is a specific announcement regarding a capital investment project rather than a general regulatory filing or a report publication announcement, it fits best under the 'Capital/Financing Update' category.
2024-02-28 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Optus Pharm regarding the decision to pay cash dividends. It specifies the dividend amount per share, the record date, the payment date, and the approval process via the upcoming general meeting of shareholders. This aligns perfectly with the definition of a 'Notice of Dividend Amount' (DIV).
2024-02-28 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of an Annual General Meeting (AGM) for Optus Pharmaceutical, detailing the date, location, and agenda items such as financial statement approval, dividend approval, and board/auditor appointments. This document serves as the official proxy solicitation and information statement sent to shareholders to inform them of the upcoming meeting and the matters to be voted upon. In the context of the provided categories, this fits the Proxy Solicitation & Information Statement (PSI) classification.
2024-02-28 Korean
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal regulatory filing submitted by Optus Pharm (옵투스제약) to report the reason for holding their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). This is a specific regulatory disclosure requirement in the Korean market regarding shareholder meeting scheduling. Since it does not contain the actual meeting materials, proxy statements, or voting results, but rather serves as a regulatory notification of scheduling, it falls under the general regulatory filing category.
2024-02-28 Korean
매출액또는손익구조30%(대규모법인은15%)이상변동
Earnings Release Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system regarding a significant change in revenue or profit structure (30% or more). It provides key financial highlights (revenue, operating profit, net income) for the fiscal year compared to the previous year. This is a standard preliminary earnings announcement (Earnings Release) required by regulatory authorities in Korea for listed companies before the final audited report is published. FY 2023
2024-01-24 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 100% confidence The document is a 'Preliminary Earnings Release' (영업(잠정)실적) for Optus Pharm, detailing quarterly financial highlights such as revenue, operating profit, and net income. It explicitly states these are preliminary figures (잠정치) and not yet audited. This fits the definition of an Earnings Release (ER), which provides initial highlights of financial results. Q4 2023
2024-01-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.